Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Airway Mucus and Asthma: The Role of MUC5AC and MUC5B.

Journal of clinical medicine

Bonser LR, Erle DJ.
PMID: 29186064
J Clin Med. 2017 Nov 29;6(12). doi: 10.3390/jcm6120112.

Asthma is characterized by mucus abnormalities. Airway epithelial hyperplasia and metaplasia result in changes in stored and secreted mucin and the production of a pathologic mucus gel. Mucus transport is impaired, culminating in mucus plugging and airway obstruction-a major...

Cite
Bonser LR, Erle DJ. Airway Mucus and Asthma: The Role of MUC5AC and MUC5B. J Clin Med. 2017;6(12)doi: 10.3390/jcm6120112.
Bonser, L. R., & Erle, D. J. (2017). Airway Mucus and Asthma: The Role of MUC5AC and MUC5B. Journal of clinical medicine, 6(12), . https://doi.org/10.3390/jcm6120112
Bonser, Luke R, and Erle, David J. "Airway Mucus and Asthma: The Role of MUC5AC and MUC5B." Journal of clinical medicine vol. 6,12 (2017). doi: https://doi.org/10.3390/jcm6120112
Bonser LR, Erle DJ. Airway Mucus and Asthma: The Role of MUC5AC and MUC5B. J Clin Med. 2017 Nov 29;6(12). doi: 10.3390/jcm6120112. PMID: 29186064; PMCID: PMC5742801.
Copy Download .nbib Format: NLM
Global Absence and Targeting of Protective Immune States in Severe COVID-19.

Research square

Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Cleary SJ, Chew NW, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF.
PMID: 33140041
Res Sq. 2020 Oct 28; doi: 10.21203/rs.3.rs-97042/v1.

While SARS-CoV-2 infection has pleiotropic and systemic effects in some patients, many others experience milder symptoms. We sought a holistic understanding of the severe/mild distinction in COVID-19 pathology, and its origins. We performed a wholeblood preserving single-cell analysis protocol...

Cite
Combes AJ, Courau T, Kuhn NF, et al. Global Absence and Targeting of Protective Immune States in Severe COVID-19. Res Sq. 2020;doi: 10.21203/rs.3.rs-97042/v1.
Combes, A. J., Courau, T., Kuhn, N. F., Hu, K. H., Ray, A., Chen, W. S., Cleary, S. J., Chew, N. W., Kushnoor, D., Reeder, G. C., Shen, A., Tsui, J., Hiam-Galvez, K. J., Muñoz-Sandoval, P., Zhu, W. S., Lee, D. S., Sun, Y., You, R., Magnen, M., Rodriguez, L., Leligdowicz, A., Zamecnik, C. R., Loudermilk, R. P., Wilson, M. R., Ye, C. J., Fragiadakis, G. K., Looney, M. R., Chan, V., Ward, A., Carrillo, S., Matthay, M., Erle, D. J., Woodruff, P. G., Langelier, C., Kangelaris, K., Hendrickson, C. M., Calfee, C., Rao, A. A., & Krummel, M. F. (2020). Global Absence and Targeting of Protective Immune States in Severe COVID-19. Research square, . https://doi.org/10.21203/rs.3.rs-97042/v1
Combes, Alexis J, et al. "Global Absence and Targeting of Protective Immune States in Severe COVID-19." Research square vol. (2020). doi: https://doi.org/10.21203/rs.3.rs-97042/v1
Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Cleary SJ, Chew NW, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF. Global Absence and Targeting of Protective Immune States in Severe COVID-19. Res Sq. 2020 Oct 28; doi: 10.21203/rs.3.rs-97042/v1. PMID: 33140041; PMCID: PMC7605560.
Copy Download .nbib Format: NLM
Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01.

EClinicalMedicine

Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B.
PMID: 34490415
EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 02.

BACKGROUND: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading to severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen...

Cite
Weiner J, Suwalski P, Holtgrewe M, et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021;40:101099doi: 10.1016/j.eclinm.2021.101099.
Weiner, J., Suwalski, P., Holtgrewe, M., Rakitko, A., Thibeault, C., Müller, M., Patriki, D., Quedenau, C., Krüger, U., Ilinsky, V., Popov, I., Balnis, J., Jaitovich, A., Helbig, E. T., Lippert, L. J., Stubbemann, P., Real, L. M., Macías, J., Pineda, J. A., Fernandez-Fuertes, M., Wang, X., Karadeniz, Z., Saccomanno, J., Doehn, J. M., Hübner, R. H., Hinzmann, B., Salvo, M., Blueher, A., Siemann, S., Jurisic, S., Beer, J. H., Rutishauser, J., Wiggli, B., Schmid, H., Danninger, K., Binder, R., Corman, V. M., Mühlemann, B., Arjun Arkal, R., Fragiadakis, G. K., Mick, E., Comet, C., Calfee, C. S., Erle, D. J., Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Langelier, C. R., Venkataramani, U., García, F., Zyla, J., Drosten, C., Alice, B., Jones, T. C., Suttorp, N., Witzenrath, M., Hippenstiel, S., Zemojtel, T., Skurk, C., Poller, W., Borodina, T., Pa-Covid, S. G., Ripke, S., Sander, L. E., Beule, D., Landmesser, U., Guettouche, T., Kurth, F., & Heidecker, B. (2021). Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine, 40101099. https://doi.org/10.1016/j.eclinm.2021.101099
Weiner, January, et al. "Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01." EClinicalMedicine vol. 40 (2021): 101099. doi: https://doi.org/10.1016/j.eclinm.2021.101099
Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 02. PMID: 34490415; PMCID: PMC8410317.
Copy Download .nbib Format: NLM
An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

Cell

Maun HR, Jackman JK, Choy DF, Loyet KM, Staton TL, Jia G, Dressen A, Hackney JA, Bremer M, Walters BT, Vij R, Chen X, Trivedi NN, Morando A, Lipari MT, Franke Y, Wu X, Zhang J, Liu J, Wu P, Chang D, Orozco LD, Christensen E, Wong M, Corpuz R, Hang JQ, Lutman J, Sukumaran S, Wu Y, Ubhayakar S, Liang X, Schwartz LB, Babina M, Woodruff PG, Fahy JV, Ahuja R, Caughey GH, Kusi A, Dennis MS, Eigenbrot C, Kirchhofer D, Austin CD, Wu LC, Koerber JT, Lee WP, Yaspan BL, Alatsis KR, Arron JR, Lazarus RA, Yi T.
PMID: 31978350
Cell. 2020 Jan 23;180(2):406. doi: 10.1016/j.cell.2020.01.003.

No abstract available.

Cite
Maun HR, Jackman JK, Choy DF, et al. An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. Cell. 2020;180(2):406doi: 10.1016/j.cell.2020.01.003.
Maun, H. R., Jackman, J. K., Choy, D. F., Loyet, K. M., Staton, T. L., Jia, G., Dressen, A., Hackney, J. A., Bremer, M., Walters, B. T., Vij, R., Chen, X., Trivedi, N. N., Morando, A., Lipari, M. T., Franke, Y., Wu, X., Zhang, J., Liu, J., Wu, P., Chang, D., Orozco, L. D., Christensen, E., Wong, M., Corpuz, R., Hang, J. Q., Lutman, J., Sukumaran, S., Wu, Y., Ubhayakar, S., Liang, X., Schwartz, L. B., Babina, M., Woodruff, P. G., Fahy, J. V., Ahuja, R., Caughey, G. H., Kusi, A., Dennis, M. S., Eigenbrot, C., Kirchhofer, D., Austin, C. D., Wu, L. C., Koerber, J. T., Lee, W. P., Yaspan, B. L., Alatsis, K. R., Arron, J. R., Lazarus, R. A., & Yi, T. (2020). An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. Cell, 180(2), 406. https://doi.org/10.1016/j.cell.2020.01.003
Maun, Henry R, et al. "An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma." Cell vol. 180,2 (2020): 406. doi: https://doi.org/10.1016/j.cell.2020.01.003
Maun HR, Jackman JK, Choy DF, Loyet KM, Staton TL, Jia G, Dressen A, Hackney JA, Bremer M, Walters BT, Vij R, Chen X, Trivedi NN, Morando A, Lipari MT, Franke Y, Wu X, Zhang J, Liu J, Wu P, Chang D, Orozco LD, Christensen E, Wong M, Corpuz R, Hang JQ, Lutman J, Sukumaran S, Wu Y, Ubhayakar S, Liang X, Schwartz LB, Babina M, Woodruff PG, Fahy JV, Ahuja R, Caughey GH, Kusi A, Dennis MS, Eigenbrot C, Kirchhofer D, Austin CD, Wu LC, Koerber JT, Lee WP, Yaspan BL, Alatsis KR, Arron JR, Lazarus RA, Yi T. An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. Cell. 2020 Jan 23;180(2):406. doi: 10.1016/j.cell.2020.01.003. PMID: 31978350.
Copy Download .nbib Format: NLM
The Type 2 Asthma Mediator IL-13 Inhibits SARS-CoV-2 Infection of Bronchial Epithelium.

American journal of respiratory cell and molecular biology

Bonser LR, Eckalbar WL, Rodriguez L, Shen J, Koh KD, Ghias K, Zlock LT, Christenson S, Woodruff PG, Finkbeiner WE, Erle DJ.
PMID: 34982656
Am J Respir Cell Mol Biol. 2022 Jan 04; doi: 10.1165/rcmb.2021-0364OC. Epub 2022 Jan 04.

Asthma is associated with chronic changes in the airway epithelium, a key target of SARS-CoV-2. Many epithelial changes, including goblet cell metaplasia, are driven by the type 2 cytokine IL-13, but the effects of IL-13 on SARS-CoV-2 infection are...

Cite
Bonser LR, Eckalbar WL, Rodriguez L, et al. The Type 2 Asthma Mediator IL-13 Inhibits SARS-CoV-2 Infection of Bronchial Epithelium. Am J Respir Cell Mol Biol. 2022;doi: 10.1165/rcmb.2021-0364OC.
Bonser, L. R., Eckalbar, W. L., Rodriguez, L., Shen, J., Koh, K. D., Ghias, K., Zlock, L. T., Christenson, S., Woodruff, P. G., Finkbeiner, W. E., & Erle, D. J. (2022). The Type 2 Asthma Mediator IL-13 Inhibits SARS-CoV-2 Infection of Bronchial Epithelium. American journal of respiratory cell and molecular biology, . https://doi.org/10.1165/rcmb.2021-0364OC
Bonser, Luke R, et al. "The Type 2 Asthma Mediator IL-13 Inhibits SARS-CoV-2 Infection of Bronchial Epithelium." American journal of respiratory cell and molecular biology vol. (2022). doi: https://doi.org/10.1165/rcmb.2021-0364OC
Bonser LR, Eckalbar WL, Rodriguez L, Shen J, Koh KD, Ghias K, Zlock LT, Christenson S, Woodruff PG, Finkbeiner WE, Erle DJ. The Type 2 Asthma Mediator IL-13 Inhibits SARS-CoV-2 Infection of Bronchial Epithelium. Am J Respir Cell Mol Biol. 2022 Jan 04; doi: 10.1165/rcmb.2021-0364OC. Epub 2022 Jan 04. PMID: 34982656.
Copy Download .nbib Format: NLM
Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19.

Research square

Tsitsiklis A, Zha B, Byrne A, DeVoe C, Levan S, Rackaityte E, Sunshine S, Mick E, Ghale R, Jauregui A, Neff N, Sarma A, Serpa P, Deiss T, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Jones N, Wu B, Darmanis S, Matthay M, Lynch S, DeRisi J, Consortium C, Hendrickson C, Kangelaris K, Krummel M, Woodruff P, Erle D, Rosenberg O, Calfee C, Langelier C.
PMID: 34013247
Res Sq. 2021 Apr 23; doi: 10.21203/rs.3.rs-380803/v1.

Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections including in patients with coronavirus disease 2019 (COVID-19). Using a combination of tracheal aspirate bulk and single-cell RNA sequencing (scRNA-seq)...

Cite
Tsitsiklis A, Zha B, Byrne A, et al. Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. Res Sq. 2021;doi: 10.21203/rs.3.rs-380803/v1.
Tsitsiklis, A., Zha, B., Byrne, A., DeVoe, C., Levan, S., Rackaityte, E., Sunshine, S., Mick, E., Ghale, R., Jauregui, A., Neff, N., Sarma, A., Serpa, P., Deiss, T., Kistler, A., Carrillo, S., Ansel, K. M., Leligdowicz, A., Christenson, S., Jones, N., Wu, B., Darmanis, S., Matthay, M., Lynch, S., DeRisi, J., Consortium, C., Hendrickson, C., Kangelaris, K., Krummel, M., Woodruff, P., Erle, D., Rosenberg, O., Calfee, C., & Langelier, C. (2021). Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. Research square, . https://doi.org/10.21203/rs.3.rs-380803/v1
Tsitsiklis, Alexandra, et al. "Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19." Research square vol. (2021). doi: https://doi.org/10.21203/rs.3.rs-380803/v1
Tsitsiklis A, Zha B, Byrne A, DeVoe C, Levan S, Rackaityte E, Sunshine S, Mick E, Ghale R, Jauregui A, Neff N, Sarma A, Serpa P, Deiss T, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Jones N, Wu B, Darmanis S, Matthay M, Lynch S, DeRisi J, Consortium C, Hendrickson C, Kangelaris K, Krummel M, Woodruff P, Erle D, Rosenberg O, Calfee C, Langelier C. Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. Res Sq. 2021 Apr 23; doi: 10.21203/rs.3.rs-380803/v1. PMID: 34013247; PMCID: PMC8132240.
Copy Download .nbib Format: NLM
Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19.

medRxiv : the preprint server for health sciences

Tsitsiklis A, Zha BS, Byrne A, Devoe C, Levan S, Rackaityte E, Sunshine S, Mick E, Ghale R, Jauregui A, Sarma A, Neff N, Serpa PH, Deiss TJ, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Jones N, Wu B, Darmanis S, Matthay MA, Lynch SV, DeRisi JL, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Rosenberg O, Calfee CS, Langelier CR.
PMID: 33791731
medRxiv. 2021 Mar 26; doi: 10.1101/2021.03.23.21253487.

Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections. Critically ill patients with coronavirus disease 2019 (COVID-19) face an elevated risk of VAP, although susceptibility varies widely. Because mechanisms...

Cite
Tsitsiklis A, Zha BS, Byrne A, et al. Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv. 2021;doi: 10.1101/2021.03.23.21253487.
Tsitsiklis, A., Zha, B. S., Byrne, A., Devoe, C., Levan, S., Rackaityte, E., Sunshine, S., Mick, E., Ghale, R., Jauregui, A., Sarma, A., Neff, N., Serpa, P. H., Deiss, T. J., Kistler, A., Carrillo, S., Ansel, K. M., Leligdowicz, A., Christenson, S., Jones, N., Wu, B., Darmanis, S., Matthay, M. A., Lynch, S. V., DeRisi, J. L., Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Erle, D. J., Rosenberg, O., Calfee, C. S., & Langelier, C. R. (2021). Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.03.23.21253487
Tsitsiklis, Alexandra, et al. "Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.03.23.21253487
Tsitsiklis A, Zha BS, Byrne A, Devoe C, Levan S, Rackaityte E, Sunshine S, Mick E, Ghale R, Jauregui A, Sarma A, Neff N, Serpa PH, Deiss TJ, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Jones N, Wu B, Darmanis S, Matthay MA, Lynch SV, DeRisi JL, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Rosenberg O, Calfee CS, Langelier CR. Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv. 2021 Mar 26; doi: 10.1101/2021.03.23.21253487. PMID: 33791731; PMCID: PMC8010763.
Copy Download .nbib Format: NLM
Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19.

bioRxiv : the preprint server for biology

van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Voyer TL, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ.
PMID: 33758859
bioRxiv. 2021 Mar 10; doi: 10.1101/2021.03.09.434529.

Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we...

Cite
van der Wijst MGP, Vazquez SE, Hartoularos GC, et al. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv. 2021;doi: 10.1101/2021.03.09.434529.
van der Wijst, M. G. P., Vazquez, S. E., Hartoularos, G. C., Bastard, P., Grant, T., Bueno, R., Lee, D. S., Greenland, J. R., Sun, Y., Perez, R., Ogorodnikov, A., Ward, A., Mann, S. A., Lynch, K. L., Yun, C., Havlir, D. V., Chamie, G., Marquez, C., Greenhouse, B., Lionakis, M. S., Norris, P. J., Dumont, L. J., Kelly, K., Zhang, P., Zhang, Q., Gervais, A., Voyer, T. L., Whatley, A., Si, Y., Byrne, A., Combes, A. J., Rao, A. A., Song, Y. S., Fragiadakis, G. K., Kangelaris, K., Calfee, C. S., Erle, D. J., Hendrickson, C., Krummel, M. F., Woodruff, P. G., Langelier, C. R., Casanova, J. L., Derisi, J. L., Anderson, M. S., & Ye, C. J. (2021). Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.03.09.434529
van der Wijst, Monique G P, et al. "Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.03.09.434529
van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Voyer TL, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv. 2021 Mar 10; doi: 10.1101/2021.03.09.434529. PMID: 33758859; PMCID: PMC7987018.
Copy Download .nbib Format: NLM
Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19.

medRxiv : the preprint server for health sciences

Tsitsiklis A, Zha BS, Byrne A, DeVoe C, Rackaityte E, Levan S, Sunshine S, Mick E, Ghale R, Love C, Tarashansky AJ, Pisco A, Albright J, Jauregui A, Sarma A, Neff N, Serpa PH, Deiss TJ, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Detweiler A, Jones NG, Wu B, Darmanis S, Lynch SV, DeRisi JL, Matthay MA, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Rosenberg O, Calfee CS, Langelier CR.
PMID: 33791731
medRxiv. 2021 Nov 30; doi: 10.1101/2021.03.23.21253487.

Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections including in patients with coronavirus disease 2019 (COVID-19). Using a combination of tracheal aspirate bulk and single-cell RNA sequencing we...

Cite
Tsitsiklis A, Zha BS, Byrne A, et al. Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv. 2021;doi: 10.1101/2021.03.23.21253487.
Tsitsiklis, A., Zha, B. S., Byrne, A., DeVoe, C., Rackaityte, E., Levan, S., Sunshine, S., Mick, E., Ghale, R., Love, C., Tarashansky, A. J., Pisco, A., Albright, J., Jauregui, A., Sarma, A., Neff, N., Serpa, P. H., Deiss, T. J., Kistler, A., Carrillo, S., Ansel, K. M., Leligdowicz, A., Christenson, S., Detweiler, A., Jones, N. G., Wu, B., Darmanis, S., Lynch, S. V., DeRisi, J. L., Matthay, M. A., Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Erle, D. J., Rosenberg, O., Calfee, C. S., & Langelier, C. R. (2021). Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.03.23.21253487
Tsitsiklis, Alexandra, et al. "Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.03.23.21253487
Tsitsiklis A, Zha BS, Byrne A, DeVoe C, Rackaityte E, Levan S, Sunshine S, Mick E, Ghale R, Love C, Tarashansky AJ, Pisco A, Albright J, Jauregui A, Sarma A, Neff N, Serpa PH, Deiss TJ, Kistler A, Carrillo S, Ansel KM, Leligdowicz A, Christenson S, Detweiler A, Jones NG, Wu B, Darmanis S, Lynch SV, DeRisi JL, Matthay MA, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Rosenberg O, Calfee CS, Langelier CR. Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv. 2021 Nov 30; doi: 10.1101/2021.03.23.21253487. PMID: 33791731; PMCID: PMC8010763.
Copy Download .nbib Format: NLM
A qPCR-based metric of Th2 airway inflammation in asthma.

Clinical and translational allergy

Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, Woodruff PG.
PMID: 23866775
Clin Transl Allergy. 2013 Jul 17;3(1):24. doi: 10.1186/2045-7022-3-24.

BACKGROUND: Using microarray profiling of airway epithelial cells, we previously identified a Th2-high molecular phenotype of asthma based on expression of periostin, CLCA1 and serpinB2 and characterized by specific inflammatory, remodeling, and treatment response features. The goal of the...

Cite
Bhakta NR, Solberg OD, Nguyen CP, et al. A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy. 2013;3(1):24doi: 10.1186/2045-7022-3-24.
Bhakta, N. R., Solberg, O. D., Nguyen, C. P., Nguyen, C. N., Arron, J. R., Fahy, J. V., & Woodruff, P. G. (2013). A qPCR-based metric of Th2 airway inflammation in asthma. Clinical and translational allergy, 3(1), 24. https://doi.org/10.1186/2045-7022-3-24
Bhakta, Nirav R, et al. "A qPCR-based metric of Th2 airway inflammation in asthma." Clinical and translational allergy vol. 3,1 (2013): 24. doi: https://doi.org/10.1186/2045-7022-3-24
Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, Woodruff PG. A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy. 2013 Jul 17;3(1):24. doi: 10.1186/2045-7022-3-24. PMID: 23866775; PMCID: PMC3724712.
Copy Download .nbib Format: NLM
The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium.

bioRxiv : the preprint server for biology

Bonser LR, Eckalbar WL, Rodriguez L, Shen J, Koh KD, Zlock LT, Christenson S, Woodruff PG, Finkbeiner WE, Erle DJ.
PMID: 33655249
bioRxiv. 2021 Feb 25; doi: 10.1101/2021.02.25.432762.

RATIONALE: Asthma is associated with chronic changes in the airway epithelium, a key target of SARS-CoV-2. Many epithelial changes are driven by the type 2 cytokine IL-13, but the effects of IL-13 on SARS-CoV-2 infection are unknown.OBJECTIVES: We sought...

Cite
Bonser LR, Eckalbar WL, Rodriguez L, et al. The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium. bioRxiv. 2021;doi: 10.1101/2021.02.25.432762.
Bonser, L. R., Eckalbar, W. L., Rodriguez, L., Shen, J., Koh, K. D., Zlock, L. T., Christenson, S., Woodruff, P. G., Finkbeiner, W. E., & Erle, D. J. (2021). The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.02.25.432762
Bonser, Luke R, et al. "The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.02.25.432762
Bonser LR, Eckalbar WL, Rodriguez L, Shen J, Koh KD, Zlock LT, Christenson S, Woodruff PG, Finkbeiner WE, Erle DJ. The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium. bioRxiv. 2021 Feb 25; doi: 10.1101/2021.02.25.432762. PMID: 33655249; PMCID: PMC7924269.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator.

bioRxiv : the preprint server for biology

Hysenaj L, Little S, Kulhanek K, Gbenedio OM, Rodriguez L, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Bahl K, Mick E, Li JZ, Ding VW, Matsumoto S, Maishan M, Simoneau C, Fragiadakis G, Jablons DM, Langelier CR, Matthay M, Ott M, Krummel M, Combes AJ, Sil A, Erle DJ, Kratz JR, Roose JP.
PMID: 34100012
bioRxiv. 2021 Jun 02; doi: 10.1101/2021.06.01.446640.

SARS coronavirus-2 (SARS-CoV-2) is causing a global pandemic with large variation in COVID-19 disease spectrum. SARS-CoV-2 infection requires host receptor ACE2 on lung epithelium, but epithelial underpinnings of variation are largely unknown. We capitalized on comprehensive organoid assays to...

Cite
Hysenaj L, Little S, Kulhanek K, et al. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv. 2021;doi: 10.1101/2021.06.01.446640.
Hysenaj, L., Little, S., Kulhanek, K., Gbenedio, O. M., Rodriguez, L., Shen, A., Lone, J. C., Lupin-Jimenez, L. C., Bonser, L. R., Serwas, N. K., Bahl, K., Mick, E., Li, J. Z., Ding, V. W., Matsumoto, S., Maishan, M., Simoneau, C., Fragiadakis, G., Jablons, D. M., Langelier, C. R., Matthay, M., Ott, M., Krummel, M., Combes, A. J., Sil, A., Erle, D. J., Kratz, J. R., & Roose, J. P. (2021). SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.06.01.446640
Hysenaj, Lisiena, et al. "SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.06.01.446640
Hysenaj L, Little S, Kulhanek K, Gbenedio OM, Rodriguez L, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Bahl K, Mick E, Li JZ, Ding VW, Matsumoto S, Maishan M, Simoneau C, Fragiadakis G, Jablons DM, Langelier CR, Matthay M, Ott M, Krummel M, Combes AJ, Sil A, Erle DJ, Kratz JR, Roose JP. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv. 2021 Jun 02; doi: 10.1101/2021.06.01.446640. PMID: 34100012; PMCID: PMC8183007.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries